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Erectile dysfunction (ED) is the consistent inability to
achieve or maintain an erection that is sufficient for
satisfactory sexual intercourse. This disorder can be
detected clinically using the International Index of
Erectile Function (IIEF) questionnaire, which has been
extensively used and verified in over 60 different lan-
guages. Nowadays, ED is increasingly recognized as
a public health problem, estimated to affect approxi-
mately 150 million men worldwide [1,2].
Metabolic syndrome (MS) is a cluster of vascular
risk factors that are independently associated with
type II diabetes and cardiovascular diseases [3–5]. The
constituents of MS include central obesity, dyslipi-
demia, hypertension and glucose intolerance. The syn-
drome is remarkably common, affecting about 24% of
American adults who are 20–70 years of age [6]. The
prevalence is expected to rise further as populations
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The purpose of this study was to determine the influence of metabolic syndrome (MS) and serum
testosterone in patients with erectile dysfunction (ED) and their possible association. A total of
103 men with ED were enrolled. The International Index of Erectile Function (IIEF) questionnaire
was used to assess erectile condition. MS was defined according to the criteria formulated by the
National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and the
International Diabetes Federation (IDF). The mean age of the study population was 57.5 ± 10.7
years, with an average IIEF of 14.7 ± 6.7. The age and prevalence of MS using the NCEP ATP III
criteria, but not the IDF criteria, were significantly different between mild and moderate/severe
ED patients (p = 0.031 and 0.009, respectively). The percentage of hypertension (78.6% vs. 36.2%;
p < 0.001) and raised fasting glucose levels (46.4% vs. 19.1%; p = 0.004) were significantly higher in
the moderate/severe ED group, and both differences remained significant in multivariate analy-
sis (p = 0.001 and 0.042, respectively). In addition, serum testosterone levels were significantly
lower in ED patients with MS (p = 0.002). In summary, the presence of MS is associated with more
severe ED. Among the components of MS, elevated blood pressure and fasting blood glucose were
independent risk factors. NCEP ATP III criteria seem to correlate better with the degree of ED
than the IDF definition. Our results also indicate that MS is associated with a lower testosterone
level in patients with ED.
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lead sedentary lifestyles and become more obese. The
existence of MS can possibly aggravate the degree of
ED by compromising penile vascular function [7,8].
Testosterone plays a role in the maintenance of male
erectile function. Low testosterone levels are an en-
docrine factor that may contribute to ED [9]. The con-
cept that MS is associated with male hypogonadism
has recently emerged [10,11]. Consequently, the cor-
relation among MS, serum testosterone levels and ED
severity is receiving increased attention. Although
studies are appearing for Caucasian men, there are lim-
ited data for Asian males. The aim of the present study
was to determine the effect of MS and serum testos-
terone in patients with ED and the relationships among
them in a Taiwanese population.
MATERIALS AND METHODS
From November 2005 to July 2006, 103 men with ED
who attended Kaohsiung Medical University Hospital
and Kaohsiung Municipal Hsiao-Kang Hospital were
enrolled. The Institutional Review Board of our hos-
pital approved the study. All of the men gave informed
consent to participate and had demographic data col-
lected, complete medical, surgical and psychosexual
histories taken, and underwent detailed physical ex-
amination and laboratory tests. Patients were inter-
viewed for ED using the IIEF questionnaire. The
erectile function domain consists of questions 1 to 5
and question 15 for assessing the global erectile func-
tion [12]. Scoring of the IIEF allowed classification of
each patient as having no (26–30), mild (17–25), mod-
erate (11–16) or severe (0–10) ED. Blood samples were
drawn between 8:00 and 11:00 AM for biochemical
and hormone analysis. Body weight (kg) and height
(cm) were measured and the body mass index (BMI)
was calculated and recorded. Waist circumference was
measured at the level of the umbilicus while the patient
breathed normally.
MS was defined using the consensus report of the
National Cholesterol Education Program Adult Treat-
ment Panel III (NCEP ATP III) [13]. According to NCEP
ATP III, MS is the presence of at least three of the fol-
lowing: abdominal obesity (waist circumference > 102
cm), hypertension (blood pressure ≥ 130/85 mmHg),
hyperglycemia (fasting blood glucose ≥ 110 mg/dL),
hypertriglyceridemia (≥150mg/dL), and reduced high-
density lipoprotein (HDL) cholesterol (< 40 mg/dL).
Another definition of MS, using the International Dia-
betes Federation (IDF) criteria [14], was also assessed
in this study. Patients were defined as having MS by
central obesity (waist circumference ≥90cm in Chinese
men) plus two of any of the following: blood pressure
≥ 130/85 mmHg, fasting plasma glucose ≥ 100 mg/dL,
serum triglyceride ≥ 150 mg/dL, and HDL cholesterol
< 40 mg/dL. A smoker was defined as a person who
smoked ≥ 10 cigarettes/day and had done so for more
than 6 months and a drinker was defined as someone
who consumed alcohol every week and had done so
for 6 consecutive months.
Patients with penile anatomic abnormalities such as
Peyronie’s disease, congenital curvature or hypospa-
dias, neuropathic changes of the penis resulting from
radical pelvic surgery or spinal cord injury, primary
hypoactive sexual desire, major psychiatric illness or
drug abuse were excluded. Results were expressed as
mean ± standard deviation and range. The values of
clinical variables were compared using χ2 test, inde-
pendent Student’s t test, and Pearson’s correlation.
Multiple logistic regression analysis was used to deter-
mine the independent factors influencing the severity
of ED. A two-tailed p value < 0.05 was considered to
be statistically significant.
RESULTS
The mean age of the study population was 57.5 ± 10.7
years (range, 30–80 years), with an average IIEF of
14.7 ± 6.7 (range, 1–25). Mean total testosterone level
was 425.6 ± 176.0 ng/dL (range, 20–804 ng/dL). The
degree of ED was categorized as mild (n = 47), mod-
erate (n = 27) and severe (n = 29) according to the IIEF
erectile function domain scores (Table 1). MS was di-
agnosed in 37% and 32% of the participants using
NCEP ATP III and IDF criteria, respectively. χ2 analysis
revealed significant differences in the percentage of MS
between groups stratified by ED severity when uti-
lizing NCEP ATP III criteria (p = 0.019) compared to
the IDF definition (p = 0.089).
Parameters between the mild and moderate/
severe ED groups were analyzed (Table 2). Patients
with moderate to severe ED were significantly older
than those with mild ED (59.6 ± 11.0 years vs.
55.0 ± 9.7 years; p = 0.031), and they also showed a
higher prevalence of MS according to NCEP ATP III
criteria (48.2% vs. 23.4%; p = 0.009). Total testosterone
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level was lower in the moderate/severe ED group
compared to the mild ED group (p = 0.059). There
were no statistically significant differences between
the two groups with regard to MS as defined by IDF
criteria, BMI, International Prostate Symptom Scores,
prostate specific antigen, cigarette smoking, and
alcohol consumption.
The components of the NCEP ATP III criteria were
further studied (Table 3). In moderate/severe ED pa-
tients, 44 (78.6%) had raised blood pressure and 26
(46.4%) had raised fasting glucose. In contrast, in the
mild ED group, only 17 (36.2%) had raised blood pres-
sure and nine (19.1%) had raised fasting blood glucose.
Both hypertension and hyperglycemia were signifi-
cantly different between the two groups (p<0.0001 and
p = 0.004, respectively). By means of logistic regression
analysis, the two components were identified as inde-
pendent risk factors for more severe ED (p = 0.001 and
0.042, respectively). Adjusted odds ratios (OR) were
5.5 (95% confidence interval [CI], 2.058–14.706) for
elevated blood pressure and 2.9 (95% CI, 1.041–8.065)
for elevated fasting glucose.
Table 1. Association between metabolic syndrome (MS) and severity of erectile dysfunction (ED)*
Severity of ED
Total (n = 103) p
Mild (n = 47) Moderate (n = 27) Severe (n = 29)
MS (NCEP ATP III) 0.019†
Yes 11 (23.4) 15 (55.6) 12 (41.4) 38 (36.9)
No 36 (76.6) 12 (44.4) 17 (58.6) 65 (63.1)
MS (IDF) 0.089
Yes 11 (23.4) 13 (48.1) 9 (31.0) 33 (32.0)
No 36 (76.6) 14 (51.9) 20 (69.0) 70 (68.0)
*Data presented as n (%); †p < 0.05. NCEP ATP III = National Cholesterol Education Program Adult Treatment Panel III; IDF =
International Diabetes Federation.
Table 2. Univariate analysis of the association between qualitative/quantitative variables and the severity of erectile
dysfunction (ED)*
Mild ED (n = 47) Moderate/severe ED (n = 56) p
Smoking 0.690
Yes 16 (34.0) 17 (30.4)
No 31 (66.0) 39 (69.6)
Drinking 0.396
Yes 10 (21.3) 16 (28.6)
No 37 (78.7) 56 (71.4)
MS (NCEP ATP III) 0.009†
Yes 11 (23.4) 27 (48.2)
No 36 (76.6) 29 (51.8)
MS (IDF) 0.085
Yes 11 (23.4) 22 (39.3)
No 36 (76.6) 34 (60.7)
Age (yr) 55.0 ± 9.7 59.6 ± 11.0 0.031†
Testosterone (ng/dL) 461.4 ± 152.1 395.7 ± 190.2 0.059
BMI (kg/m2) 24.9 ± 2.6 24.8 ± 3.0 0.884
IPSS 6.5 ± 6.0 7.0 ± 6.2 0.695
PSA (ng/mL) 1.6 ± 1.2 1.8 ± 2.0 0.616
*Data presented as n (%) or mean ± standard deviation; †p < 0.05. MS = metabolic syndrome; NCEP ATP III = National Cholesterol
Education Program Adult Treatment Panel III; IDF = International Diabetes Federation; BMI = body mass index; IPSS = International
Prostate Symptom Score; PSA = prostate specific antigen.
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Patients divided into two groups according to the
presence of MS were also analyzed (Table 4). ED was
significantly more severe in patients with MS defined
by NCEP ATP III criteria (IIEF = 12.7 ± 5.7 vs. 15.8 ± 7.0;
p=0.022). There was still no significant difference with
the IDF definition. In ED patients with MS, BMI was
significantly higher and serum testosterone was sig-
nificantly lower compared to ED patients without MS
(p = 0.006 and 0.002, respectively). The association was
the same when using the IDF definition. Finally, total
testosterone levels were significantly inversely corre-
lated with BMI (r = −0.354, p = 0.0002) and waist cir-
cumference (r = −0.226, p = 0.022), but the correlation
with age was insignificant (p = 0.493).
DISCUSSION
MS is traditionally used to identify individuals who
have increased metabolic and atherosclerotic risk.
Men with MS have a two- to fourfold increased risk
of cardiovascular disease [4,5]. Using NCEP ATP III
criteria, we found that MS is a rather common condi-
tion in patients with ED, with an incidence of 37%,
similar to the results of Bansal et al [15]. The inci-
dence of MS in patients with moderate-to-severe ED
was even higher, at nearly half of the studied popula-
tion (48.2%). The result consolidates the idea that 
a routine survey for MS in patients with ED can be
feasible and effective in detecting cardiovascular risk
markers.
Several studies have demonstrated the strong as-
sociation between ED and MS [7,15–17]. Seftel et al
concluded that ED shared common risk factors with
cardiovascular diseases [16]. Esposito et al reported
that men with MS had an increased prevalence of ED
[7]. Demir et al stated that MS has to be accepted as 
a new risk factor for ED [17]. In our patients with ED,
those with MS were characterized by worse erectile
function (IIEF = 12.7 ± 5.7 in patients with MS vs.
15.8 ± 7.0 in patients without MS; p = 0.022). Namely,
there is a significant association between severity of
ED and MS.
MS is a constellation of cardiovascular risk factors
that are related to endothelial dysfunction [8,18]. Penile
erection essentially relies on the release of nitric oxide
(NO) by endothelial cells [19]. Accordingly, the associ-
ation between ED and MS is supposed to result from
endothelial dysfunction [7,8,19,20]. Of note, both en-
dothelial and ED were responsive to a weight loss and
exercise program [21]. Correction of multiple metabolic
abnormalities, particularly with lifestyle changes, is
required to improve both conditions [21,22]. Increased
awareness is needed, especially when many of the
components of MS are not considered to be diseases
by the general population.
In 2005, the IDF formulated a substantial revision
of earlier MS criteria [14]. The characteristics of the
Table 3. Relationship between each component of the metabolic syndrome (as defined by National Cholesterol
Education Program Adult Treatment Panel III criteria) and severity of erectile dysfunction (ED)*
Mild ED (n = 47) Moderate/severe ED (n = 56) p
Raised blood pressure < 0.001†
Yes 17 (36.2) 44 (78.6)
No 30 (63.8) 12 (21.4)
Raised fasting glucose 0.004†
Yes 9 (19.1) 26 (46.4)
No 38 (80.9) 30 (53.6)
Raised waist circumference 0.858
Yes 2 (4.3) 2 (3.6)
No 45 (95.7) 54 (96.4)
Reduced HDL cholesterol 0.605
Yes 34 (72.3) 43 (76.7)
No 13 (27.7) 13 (23.3)
Raised triglyceride 0.290
Yes 13 (27.7) 21 (37.5)
No 34 (72.3) 35 (62.5)
*Data presented as n (%); †p < 0.05. HDL = high-density lipoprotein.
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IDF definition are indispensability of central obesity,
ethnicity-specific values of waist circumference, and
lowering diagnostic cutoff values for fasting plasma
glucose. However, in our study, the IDF criteria failed
to reveal a significant association between MS and
severity of ED (p=0.085). NCEP ATP III criteria seemed
to be a more sensitive indicator of MS and a better
predictor of ED severity than the IDF definition. The
essential, not optional, composition of visceral obesity
in the IDF guidelines may miss some patients who are
relatively lean.
We further investigated the relationship between
the components of MS and ED severity, and found
that hypertension and glucose intolerance are the key
elements that exacerbated the degree of ED. The age-
adjusted OR of elevated blood pressure and fasting
blood glucose were 5.5 and 2.9 for a more severe ED,
respectively. Observational studies have described the
association between both conditions and ED [23–28].
In a large database of 272,325 patients with ED, 42%
had hypertension and 20% had diabetes [16]. In a
survey of 7,689 men, Giuliano et al reported that 67%,
71%, and 77% of patients with hypertension alone,
diabetes alone, and both diseases, respectively, had
ED [28]. They concluded that patients with hyper-
tension and/or diabetes have a high prevalence of
bothersome, untreated ED.
ED is not an unusual complication in patients
with diabetes, which is attributed to autonomic neu-
ropathy and peripheral vascular disease [27]. Hyper-
glycemia activates various molecular pathways, such
as decreased endothelial NO synthase (eNOS) expres-
sion, reduced bioavailability of eNOS cofactor tetra-
hydrobiopterin, impaired eNOS phosphorylation,
activated oxidative stress, and heightened vasocon-
striction, resulting in endothelial injury [29]. An in-
creased incidence of ED in hypertensive men has also
been well established in previous studies [23,24,28].
Both endothelial and non-endothelium-dependent
impairment of vasodilatation contributes to ED in hy-
pertensive patients [30]. A hypertensive state and poor
blood glucose control may lead to more severe ED
through affecting the penile vascular bed.
A reduction in total testosterone level is a conse-
quence of male aging, and is estimated to occur at a
rate of 1% reduction annually after the third decade
of life [31]. However, the magnitude of the decrease
does not vary significantly with age. This was also
found in our study. Recently, it has been recognized
that a low testosterone level is associated with obe-
sity and MS [10,11,32,33]. Tsai et al reported that low
testosterone is a predictor of increased visceral fat
[32]. In a review of world literature from 1988 to 2004,
Makhsida et al found that MS is strongly associated
Table 4. Univariate analysis of the association between qualitative/quantitative variables and metabolic syndrome
(MS) in patients with erectile dysfunction*
Patients with MS† (n = 38) Patients without MS (n = 65) p
Smoking 0.690
Yes 9 (23.7) 24 (36.9)
No 29 (76.3) 41 (63.1)
Drinking 0.396
Yes 12 (31.6) 14 (21.5)
No 26 (68.4) 51 (78.5)
Age (yr) 59.5 ± 9.6 56.3 ± 11.1 0.147
Testosterone (ng/dL) 356.1 ± 167.4 466.3 ± 169.4 0.002‡
BMI (kg/m2) 25.9 ± 2.9 24.3 ± 2.6 0.006‡
IPSS 6.3 ± 5.6 7.0 ± 6.4 0.610
PSA (ng/mL) 1.4 ± 2.4 1.8 ± 1.2 0.336
IIEF 12.7 ± 5.7 15.8 ± 7.0 0.022‡
*Data presented as n (%) or mean ± standard deviation; †defined by National Cholesterol Education Program Adult Treatment Panel
III; ‡p < 0.05. BMI = body mass index; IPSS = International Prostate Symptom Score; PSA = prostate specific antigen; IIEF =
International Index of Erectile Function.
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with hypogonadism in men [11]. They suggested that
hypogonadism is likely to be a fundamental compo-
nent of MS. Kaplan et al indicated that the combina-
tion of obesity and MS has a major exacerbating impact
on the age-related decrease in testosterone levels [33].
Our results showed that total testosterone level is sig-
nificantly lower in patients with MS and is inversely
correlated with BMI and waist circumference (whether
ATP III or IDF criteria), supporting their relation in
ED patients.
It is not well understood whether hypotestos-
teronemia causes MS or vice versa. Testosterone in-
hibits the differentiation of preadipocytes into mature
adipocytes via androgen receptors, which are more
abundant in visceral adipocytes [34]. Furthermore,
testosterone can improve insulin sensitivity via a re-
duction in circulating non-esterified fatty acids by in-
hibiting lipoprotein lipase activity [35]. Therefore, a
low testosterone level may lead to central obesity, in-
sulin resistance and MS. On the contrary, adipose tis-
sue produces more leptin and aromatase, resulting in
reduced testosterone production and increased es-
tradiol conversion [11]. The hyperinsulinemia of MS
may lead to androgen decline by inhibiting sex hor-
mone-binding globulin [36]. This explains why obese
or metabolically abnormal men have lower testos-
terone levels [33,37]. In any case, there is increasing
evidence of the beneficial role that androgen replace-
ment therapy plays in decreasing the risk of MS and
associated cardiovascular morbidities [38].
In conclusion, the presence of MS is associated with
more severe ED. Among the elements of MS, those
that are independently associated with ED severity are
hypertension and raised fasting blood glucose. Rec-
ognizing ED that is complicated by MS can help phy-
sicians to identify individuals who are candidates for
lifestyle modification and appropriate treatment of
underlying cardiovascular risk factors. NCEP ATP III
criteria appear to correlate better with the degree of
ED than IDF criteria. Nevertheless, both definitions of
MS are inversely correlated with serum testosterone
levels, and future studies are needed to explain the
underlying mechanism.
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